Key result
β2-AR internalization protects against cardiac hypertrophy by inhibiting Golgi PLCε signaling via Gi and ERK.
Why the study?
Chronic activation of beta1-ARs drives detrimental cardiac remodeling while beta2-AR signaling is protective, but the underlying molecular mechanisms for cardiac protection through beta2-ARs remain unclear.
Internalized β2-ARs protect against cardiac hypertrophy by inhibiting PLCε signaling at the Golgi apparatus, providing a molecular mechanism for the protective effects of β2-AR signaling in heart failure.
Internalized β2-AR signaling may protect against hypertrophy in models; hypothesis-generating for endosomal Gi/ERK targets in human HF.
Chronically elevated neurohumoral drive, and particularly elevated adrenergic tone leading to β-adrenergic receptor (β-AR) overstimulation in cardiac myocytes, is a key mechanism involved in the progression of heart failure. β1-AR and β2-ARs are the two major subtypes of β-ARs present in the human heart, however, they elicit different or even opposite effects on cardiac function and hypertrophy. For example, chronic activation of β1ARs drives detrimental cardiac remodeling while β2AR signaling is protective. The underlying molecular mechanisms for cardiac protection through β2ARs remain unclear. Here we show that β2-AR protects against hypertrophy through inhibition of PLCε signaling at the Golgi apparatus. The mechanism for β2AR-mediated PLC inhibition requires internalization of β2AR, activation of Gi and Gβγ subunit signaling at endosomes and ERK activation. This pathway inhibits both angiotensin II and Golgi-β1-AR-mediated stimulation of phosphoinositide hydrolysis at the Golgi apparatus ultimately resulting in decreased PKD and HDAC5 phosphorylation and protection against cardiac hypertrophy. This reveals a mechanism for β2-AR antagonism of the PLCε pathway that may contribute to the known protective effects of β2-AR signaling on the development of heart failure.
No takes yet. Share an insight, caveat, or question.
Wei et al. (2023) studied Cardiac hypertrophy and heart failure. β2-adrenergic receptor (β2-AR) signaling was evaluated on Inhibition of PLCε signaling and protection against cardiac hypertrophy. Internalization of β2-AR protects against cardiac hypertrophy by inhibiting PLCε signaling at the Golgi apparatus via activation of Gi, Gβγ subunit signaling at endosomes, and ERK.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: